Fidelis Capital Partners LLC Increases Stake in Boston Scientific Co. (NYSE:BSX)

Fidelis Capital Partners LLC raised its position in Boston Scientific Co. (NYSE:BSX) by 46.5% in the 4th quarter, Holdings Channel reports. The fund owned 13,036 shares of the medical equipment provider’s stock after acquiring an additional 4,138 shares during the period. Fidelis Capital Partners LLC’s holdings in Boston Scientific were worth $754,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Western Wealth Management LLC lifted its position in Boston Scientific by 6.6% in the fourth quarter. Western Wealth Management LLC now owns 16,928 shares of the medical equipment provider’s stock valued at $979,000 after purchasing an additional 1,043 shares during the period. Xponance Inc. lifted its holdings in shares of Boston Scientific by 7.0% in the 4th quarter. Xponance Inc. now owns 191,998 shares of the medical equipment provider’s stock valued at $11,099,000 after buying an additional 12,537 shares during the period. AIA Group Ltd lifted its holdings in shares of Boston Scientific by 86.4% in the 4th quarter. AIA Group Ltd now owns 22,317 shares of the medical equipment provider’s stock valued at $1,290,000 after buying an additional 10,346 shares during the period. Cambridge Trust Co. boosted its stake in shares of Boston Scientific by 14.7% in the fourth quarter. Cambridge Trust Co. now owns 3,647 shares of the medical equipment provider’s stock valued at $211,000 after buying an additional 467 shares in the last quarter. Finally, Twin Capital Management Inc. grew its holdings in Boston Scientific by 8.6% during the fourth quarter. Twin Capital Management Inc. now owns 22,996 shares of the medical equipment provider’s stock worth $1,329,000 after acquiring an additional 1,816 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the topic of several research analyst reports. Raymond James boosted their target price on shares of Boston Scientific from $67.00 to $73.00 and gave the stock a “strong-buy” rating in a research report on Thursday, February 1st. JPMorgan Chase & Co. increased their target price on shares of Boston Scientific from $60.00 to $72.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Mizuho upgraded Boston Scientific from a “neutral” rating to a “buy” rating and upped their price target for the stock from $65.00 to $80.00 in a report on Thursday, February 1st. Royal Bank of Canada lifted their price objective on Boston Scientific from $70.00 to $78.00 and gave the stock an “outperform” rating in a report on Monday. Finally, Wells Fargo & Company upped their target price on Boston Scientific from $70.00 to $72.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Two equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $68.50.

Insider Activity

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $66.89, for a total transaction of $467,092.87. Following the completion of the sale, the executive vice president now directly owns 56,508 shares in the company, valued at $3,779,820.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total transaction of $467,092.87. Following the completion of the sale, the executive vice president now owns 56,508 shares of the company’s stock, valued at approximately $3,779,820.12. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Daniel J. Brennan sold 13,662 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $65.86, for a total transaction of $899,779.32. Following the sale, the chief financial officer now owns 271,542 shares of the company’s stock, valued at $17,883,756.12. The disclosure for this sale can be found here. Insiders sold 50,979 shares of company stock valued at $3,418,529 in the last ninety days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 0.1 %

Boston Scientific stock traded up $0.08 during trading on Friday, hitting $67.50. The company’s stock had a trading volume of 1,788,802 shares, compared to its average volume of 6,307,019. The stock’s fifty day moving average is $67.21 and its 200 day moving average is $59.74. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.82 and a current ratio of 1.32. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $69.21. The stock has a market capitalization of $99.03 billion, a price-to-earnings ratio of 63.01, a P/E/G ratio of 2.38 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.51 by $0.04. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. The business had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.59 billion. During the same period in the prior year, the firm posted $0.45 EPS. As a group, equities research analysts predict that Boston Scientific Co. will post 2.25 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.